Adams Clinical Boston

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Depression12 trials
• Alzheimer disease5 trials

Phase

• Phase 314 trials
• Phase 22 trials

Status

• Recruiting8 trials
• Active, not recruiting6 trials
• Completed1 trial
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Cybin IRL Limited3 trials
• Hoffmann-La Roche3 trials
• Definium Therapeutics US, Inc.2 trials
• Xenon Pharmaceuticals Inc.2 trials
• and 3 more

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Eli Lilly and Company· Source

  Contact: Darin Dougherty (principal investigator)

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

  Contact: Darin Dougherty (principal investigator)

• Recruiting

  A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  NCT07592689· Phase 3· Definium Therapeutics US, Inc.· Source

  Contact: Definium Therapeutics Clinical Trials Info Requests

• Recruiting

  A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  NCT07573176· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

  Contact: Dyanna Domilici (principal investigator)

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Cybin IRL Limited· Source

  Contact: Participant Navigators

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Cybin IRL Limited· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  NCT07076407· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

  NCT06941844· Phase 3· Definium Therapeutics US, Inc.· Source

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

  NCT06847321· Phase 2· Lighthouse Pharmaceuticals, Inc.· Source

  Contact: Megan Norris

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Triage Survey for Psychiatry Research Eligibility

  NCT05800925· Adams Clinical· Source

  Contact: Karla Meehan, MA

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression7 recruiting
• Alzheimer disease3 recruiting

Closed trials

• Completed

  "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

  NCT06564818· Phase 3· Cybin IRL Limited· Source